As of January, Dr Payam Gammage's lab begun their NIH MERIT R37 Award with the National Cancer Institute in the US. This award, held jointly with the lab of Dr Ed Reznik at the Memorial Sloan Kettering Cancer Center, will allow the team to define the function of complex I truncating mutations in cancer. Complex I mutations are particularly abundant in colorectal, thyroid and kidney cancers and, alongside a range of other mitochondrial DNA mutations that are present in ~60% of all cancers in total, remain poorly understood. The award is worth ~$4.5M over 7 years (2023-2029) and the team will be split evenly between Glasgow and New York.